On Demand 2021 Monday General Sessions

This collection covers general sessions from Monday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Plenary - Implementing New Guidelines Into Practice
  • 7 for 11: Hot Topics in Dermatology
  • Allergen Mixing in the Allergist’s Office - The Changing Environment in Allergy and Immunology Extract Mixing
  • The Growing Epidemic of Secondary Immunodeficiency
  • Addressing Non-IgE Mediated Food Allergy
  • Allergen Mixing in the Allergist’s Office - The Compliant Mixing Room
  • Starting an OIT Program in Private Practice from the Ground Up

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 10.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this program, participants should be able to:

  • Discuss and review the new Drug Allergy Practice Parameter
  • Analyze and provide practical tools for changes in testing and management of EoE
  • Describe the new changes to the NHLBI Guidelines for the treatment of asthma
  • Distinguish secondary immunodeficiency from primary immunodeficiency
  • Recognize the association between lymphoma and secondary immunodeficiency
  • Identify the association between B cell-depleting therapies and hypogammaglobulinemia
  • Identify the diagnostic and management challenges of complex FPIES and EoE patients
  • Describe the nutritional challenges in FPIES and EoE patients
  • Discuss history taking, diagnostic and treatment options for complex FPIES and EoE patients
  • Detail the necessary logistics to starting OIT in a busy practice setting, including space, staff, and implementation of protocols
  • Highlight the role of additional allergists to help facilitate already existing protocols and build on them
  • Discuss the desire of patients for additional foods and a wider patient population for OIT protocols, and the implementation of these newer protocols in practice
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Course opens: 
11/19/2021
Course expires: 
11/18/2024
Rating: 
0

Marcella R. Aquino, MD, FACAAI
Aikaterini Anagnostou, MD, PhD, FACAAI
Ignacio Ansotegui, MD, PhD
Alan P. Baptist, MD, MPH
Alexia K. Beauregard, RD
Jaclyn Bjelac, MD 
Antonella Cianferoni, MD, FACAAI
Timothy J. Craig, DO, FACAAI
Tara Doran, RN, MHA
Melissa D. Gans, MD
Alexandra Golant, MD
Justin C. Greiwe, MD, FACAAI
Brian T. Kelly, MD, MA, FACAAI
David A. Khan, MD, FACAAI 
Donald Y. M. Leung, MD, PhD, FACAAI
Jay A. Lieberman, MD, FACAAI
Kelly M. Maples, MD, FACAAI
Bryan Martin, DO, FACAAI
Syed Shahzad Mustafa, MD, FACAAI
Michael R. Nelson, MD, PhD, FACAAI
Anna H. Nowak-Wegrzyn, MD, FACAAI
Maureen M. Petersen, MD, FACAAI
Andrej A. Petrov, MD, FACAAI
John M. Routes, MD, FACAAI
Sarbjit S. Saini, MD
Brian C. Schroer, MD
David J. Schwartz, MD
Marc Serota, MD
David R. Stukus, MD, FACAAI
Kristin C. Sokol, MD, FACAAI
Sarah Spriet DO, FACAAI
James L. Sublett, MD, FACAAI
Richard L. Wasserman, MD, PhD, FACAAI 
Jolan Walter, MD, PhD

Available Credit

  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Please login or create an account to take this course.